Hims & Hers Health Inc. (HIMS) Stock Analysis 2026

Hims & Hers is a telehealth platform connecting patients with licensed healthcare providers for treatments across sexual health, hair loss, mental health, skincare, and weight management (GLP-1 medications). The company operates a direct-to-consumer model, selling branded and compounded medications alongside its telehealth consultations. With a vertically integrated pharmacy model, Hims & Hers disrupts traditional healthcare by combining consultations with medication delivery in a single low-friction experience.

This chart shows how Hims & Hers Health's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Hims & Hers Health Inc. doesn't carry a meaningful trailing P/E right now, generates $849.4M in free cash flow, runs a debt/equity ratio of 477.13, and converts shareholder equity into profit at a -32.0% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Wall Street analysts covering Hims & Hers Health Inc. currently haven't converged on a clear consensus rating, with a mean 12-month price target of $31.23. Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

We use 1 valuation model to estimate HIMS's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

HIMS is currently in a mixed technical position. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

HIMS's investment case breaks down into 4 bull points and 4 bear points below. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks. A strong bull case with manageable bear risks typically makes for a more compelling investment.